BioSig Unveils Groundbreaking Updates to PURE EP Platform at ... - Best Stocks
| SEZI Stock | SEK 6.26 0.06 0.97% |
Slightly above 53% of Senzime AB's investor base is interested to short. The analysis of current outlook of investing in Senzime AB suggests that many traders are impartial regarding Senzime AB's prospects. Senzime AB's investing sentiment can be driven by a variety of factors including economic data, Senzime AB's earnings reports, geopolitical events, and overall market trends.
Senzime |
BioSig Unveils Groundbreaking Updates to PURE EP Platform at ... Best Stocks
Read at news.google.com
 |
Senzime AB Fundamental Analysis
We analyze Senzime AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Senzime AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Senzime AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Senzime AB is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Senzime AB Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Senzime AB stock to make a market-neutral strategy. Peer analysis of Senzime AB could also be used in its relative valuation, which is a method of valuing Senzime AB by comparing valuation metrics with similar companies.
Peers
Senzime AB Related Equities
| EPIS-B | Episurf Medical | 7.14 | ||||
| XBRANE | Xbrane Biopharma | 5.56 | ||||
| CRAD-B | C Rad | 4.49 | ||||
| BOUL | Boule Diagnostics | 1.28 | ||||
| XSPRAY | XSpray Pharma | 2.59 |
Additional Tools for Senzime Stock Analysis
When running Senzime AB's price analysis, check to measure Senzime AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Senzime AB is operating at the current time. Most of Senzime AB's value examination focuses on studying past and present price action to predict the probability of Senzime AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Senzime AB's price. Additionally, you may evaluate how the addition of Senzime AB to your portfolios can decrease your overall portfolio volatility.